News
03-29-2017, 06:53 AM
On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
More... (http://www.news-medical.net/news/20170329/FDA-approves-new-therapy-for-adult-patients-with-relapsing-and-primary-progressive-MS.aspx)
More... (http://www.news-medical.net/news/20170329/FDA-approves-new-therapy-for-adult-patients-with-relapsing-and-primary-progressive-MS.aspx)